Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial
Roland Tschismarov, Pierre Van Damme, Clara Germain, Ilse De Coster, Mathieu Mateo, Stéphanie Reynard, Alexandra Journeaux, Yvonne Tomberger, Kanchanamala Withanage, Denise Haslwanter, Katherine Terler, Sabrina Schrauf, Matthias Müllner, Erich Tauber, Katrin Ramsauer, Sylvain Baize
Topics & Concepts
TolerabilityMedicineLassa feverAdverse effectPlaceboLassa virusClinical endpointClinical trialMeaslesInternal medicineImmunogenicityEuropean unionRandomized controlled trialVirologyImmunologyVaccinationPathologyAntigenVirusAlternative medicineEconomic policyDiseaseBusinessViral Infections and Outbreaks ResearchImmune responses and vaccinationsVaccine Coverage and Hesitancy